Unknown

Dataset Information

0

Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry.


ABSTRACT:

Objective

To explore real-life use of glucose lowering drugs and prognosis after acute myocardial infarction (AMI) with a special focus on metformin.

Methods

Patients (n?=?70270) admitted for AMI 2012-2017 were stratified by diabetes status and glucose lowering treatment and followed for mortality and MACE+ (AMI, heart failure (HF), stroke, mortality) until end of 2017 (mean follow-up time 3.4?±?1.4?years) through linkage with national registries and SWEDEHEART. Hazard ratios (HR) were calculated in adjusted Cox proportional hazard regression models.

Results

Mean age was 68?±?11?years and 70% were male. Of patients with diabetes (n?=?16356; 23%), a majority had at least one glucose lowering drug (81%) of whom 51% had metformin (24% monotherapy), 43% insulin and a minority any SGLT2i/GLP-1 RA (5%). Adjusted HR for patients with versus without diabetes was 1.31 (95% CI 1.27-1.36) for MACE+ and 1.48 (1.41-1.56) for mortality. Adjusted HR for MACE+ for diabetes patients on metformin was 0.92 (0.85-0.997), p?=?0.042 compared to diet treated diabetes.

Conclusion

Diabetes still implies a high complication risk after AMI. Metformin and insulin were the most common treatment used in almost half of the diabetes population. Furthermore, patients treated with metformin had a lower cardiovascular risk after AMI and needs to be confirmed in prospective controlled trials.

SUBMITTER: Ritsinger V 

PROVIDER: S-EPMC7919225 | biostudies-literature | 2020 Nov-Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry.

Ritsinger Viveca V   Lagerqvist Bo B   Lundman Pia P   Hagström Emil E   Norhammar Anna A  

Diabetes & vascular disease research 20201101 6


<h4>Objective</h4>To explore real-life use of glucose lowering drugs and prognosis after acute myocardial infarction (AMI) with a special focus on metformin.<h4>Methods</h4>Patients (<i>n</i> = 70270) admitted for AMI 2012-2017 were stratified by diabetes status and glucose lowering treatment and followed for mortality and MACE+ (AMI, heart failure (HF), stroke, mortality) until end of 2017 (mean follow-up time 3.4 ± 1.4 years) through linkage with national registries and SWEDEHEART. Hazard rati  ...[more]

Similar Datasets

| S-EPMC6009178 | biostudies-literature
| S-EPMC10156703 | biostudies-literature
| S-EPMC8031406 | biostudies-literature
| S-EPMC6394466 | biostudies-literature
| S-EPMC8342504 | biostudies-literature
| S-EPMC5779025 | biostudies-literature
| S-EPMC8183232 | biostudies-literature
| S-EPMC4845135 | biostudies-other
| S-EPMC9851450 | biostudies-literature
| S-EPMC10804591 | biostudies-literature